CN101972429A - Compound preparation for treating stroke and preparation method thereof - Google Patents
Compound preparation for treating stroke and preparation method thereof Download PDFInfo
- Publication number
- CN101972429A CN101972429A CN2010105332931A CN201010533293A CN101972429A CN 101972429 A CN101972429 A CN 101972429A CN 2010105332931 A CN2010105332931 A CN 2010105332931A CN 201010533293 A CN201010533293 A CN 201010533293A CN 101972429 A CN101972429 A CN 101972429A
- Authority
- CN
- China
- Prior art keywords
- preparation
- flos
- compound recipe
- compound preparation
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound preparation for treating stroke and a preparation method thereof. The compound preparation is prepared from 19 Mongolian medicinal materials including agilawood, medicine terminalia fruit and the like. The preparation can be formed into pills, tablets, granules, capsules and the like and has the effects of smoothing the white vein and black vein, restoring consciousness and saving life. The compound preparation has protect effects on stroke, particularly reperfusion injury; and the compound preparation can lower the methylene dioxyamphetamine (MDA) content of rats with middle cerebral artery occlusion reperfusion (MCAO/R), improve the superoxide dismutase (SOD) activity of brain tissues, increase the reduced glutathione (GSH) content of the brain tissues and conduct a function of anti-free radical damage brain tissue protection, and also can inhibit the expression of infarct focus caspase-3 of the brain tissues of the rats with middle cerebral artery occlusion reperfusion (MCAO/R), increase the expression of antiapoptotic protein bcl-2, improve the nervous function of the rats with middle cerebral artery occlusion reperfusion (MCAO/R) and relieves the symptoms of central neuron damage caused cerebral ischemia. The compound preparation of the invention can be used for preparing medicaments for treating stroke.
Description
Technical field
Patent of the present invention relates to a kind of compound preparation, is used for the treatment of apoplexy.Comprise prescription composition, dosage, production technology and drug effect.
The main purpose of patent of the present invention is that clinical a kind of compound preparation for the treatment of apoplexy, the life of redemption patients with cerebral apoplexy of providing is provided.
Background technology
Apoplexy, particularly cerebral infarction are the diseases of serious threat human health, have the characteristics of high incidence, high disability rate and high mortality, and its pathogenic factors is many and complicated.The current death toll of apoplexy accounts for 10% of global death toll, and the incidence rate of estimating following 10 years will rise gradually.Have 50%～70% patient to leave over handicaps such as paralysis, aphasia among the survivor, the apoplexy sequela is given the medical economics burden increase day by day that society and family bring for a long time.Though some Western medicine mechanisms of action are clear, because of its action target spot is single, curative effect is undesirable, still lacks effective medicine at present clinically.Searching has the medicine of obvious prevention and therapeutical effect to have the important clinical meaning to apoplexy.The mongolian medicine prescription is used wide in the Meng ethnic group area, good effect; Ischemic cerebrovascular, the Mongolian medicine is called " Sa disease ", " aortic arch syndrome ".The traditional Mongolian medicine theory thinks that " Sa disease " belongs to the aortic arch syndrome category, is because stagnation of QI-blood causes black arteries and veins (blood vessels) to block, and makes the sea-brain of the lung-pulse lose function and falls ill.This disease is suddenly to fall in a swoon, and is unconscious, facial hemiparalysis, and speech is unfavorable, and hemiplegia is the disease of feature.Mongolian medicine's treatment " Sa disease " is similar to the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs of Chinese traditional treatment Blood stasis, with blood circulation promoting and blood stasis dispelling, and the mediation sering, it is main setting upright beneficial brain.Studies show that in a large number that in recent years ethnic drug has original advantage because of the many target spots of its multicomponent aspect the protection of cerebral ischemia reperfusion injury.
Compound recipe of the present invention is made up of Fructus Chebulae, Rhizoma Picrorhizae, Artemisia frigida Willd. etc. 19 flavor medical materials, has to regulate conspicuously to strive according to, sticking, heat friendship, Gu three, short balance has blood circulation promoting and blood stasis dispelling, tranquillizing and allaying excitement, correction stupor, controls irritability, mediation the lung-pulse, Hei Mai, the effect of the continuous life of refreshment, can control brain and suffer from, more the sea of the lung-pulse.Main feature: short treating period, good effect and stablize, have no side effect.Production technology is simple, cheap.
Summary of the invention
The object of the present invention is to provide that a kind of compatibility is reasonable, curative effect is good, the compound recipe of the treatment apoplexy that has no side effect.The prescription of patent of the present invention is formed and dosage:
Among the present invention; the weight proportion relation of each principal agent is: Fructus Chebulae 30g～60g; Rhizoma Picrorhizae 20g～50g; Flos Caryophylli, Semen Myristicae, the Radix Aucklandiae, Rhizoma Bistortae, Radix Glehniae are 10g～30g, and Artemisia frigida Willd., Lignum Santali Albi, Concretio Silicea Bambusae, Resina Liquidambaris, HEIYUNXIANG, dried Cor Leporis, Lignum Aquilariae Resinatum, Flos Inulae, Flos Bombacis Malabarici, artificial Calculus Bovis, Semen Strychni (processed), Radix Aconiti Kusnezoffii Preparata are 2g～20g.
Another object of the present invention is to provide a kind of method for preparing compound active of the present invention.
The preparation method of active component of the present invention can realize in the following way: after taking by weighing the crude drug mix homogeneously by weight and pulverizing slightly, decocts with water and extracts 3 times, and each 1.5～2 hours, add water 2～4 parts by volume, merges three times extracting solution, centrifugal going precipitated.Supernatant adds 3 times of amounts of dehydrated alcohol, fully stirs, and decompress filter, the filtrate partial rotation is evaporated to nothing alcohol flavor and obtains sample.Be ground into coarse powder, merge,, filter, merge water boiling and extraction liquid with water boiling and extraction, concentrating under reduced pressure, drying is pulverized, and gets active component.
Compound recipe of the present invention has the effect of treatment apoplexy, can be used for preparing the effect with treatment and prevention of brain apoplexy.
It is the compound recipe with dispelling toxins and dredging collaterals effect that is formed by Fructus Chebulae, Rhizoma Picrorhizae, Rhizoma Bistortae, Semen Myristicae compatibility, can effectively dispel the secondary lesion of the metabolism toxicant of cerebral ischemia generation to cerebral ischemia kitchen range and ischemia half blanking bar neurocyte.Thereby alleviate tardy property nerve cell death, eliminate or alleviate the pathologic basis of sequela.Be mainly used in the treatment of apoplexy such as cerebral embolism.
The concrete operations example:
Take by weighing Fructus Chebulae 25g, Rhizoma Picrorhizae 20g Flos Caryophylli, Semen Myristicae, the Radix Aucklandiae, Rhizoma Bistortae, each 10g of Radix Glehniae, Artemisia frigida Willd., Lignum Santali Albi, Concretio Silicea Bambusae, Resina Liquidambaris, HEIYUNXIANG, each 5g of dried Cor Leporis, Lignum Aquilariae Resinatum, Flos Inulae, Flos Bombacis Malabarici, artificial Calculus Bovis, Semen Strychni (processed), Radix Aconiti Kusnezoffii Preparata (former side is the Radix Aconiti Kusnezoffii bud) 2.5g.Mix homogeneously decocts with water and extracts 3 times after also pulverizing slightly, and each 1.5～2 hours, add water 2～4 parts by volume, merge three times extracting solution, the centrifugal precipitation of going.Supernatant adds 3 times of amounts of dehydrated alcohol, fully stir, decompress filter, the filtrate partial rotation be evaporated to no alcohol distinguish the flavor of the compound active composition.
The main pharmacodynamics test of compound recipe of the present invention
1, to the influence of MCAO rat nervous symptoms
Experiment has adopted improvement line bolt legal system to make the rat cerebral ischemia model, and MCAO rat nervous symptoms evaluation results shows after the modeling: investigational agent 200mg/kg (be equivalent to clinical people's consumption 10 times) has improved MCAO rat nervous symptoms.(P＜0.01 or P＜0.05)
2, to the morphologic influence of MCAO rat cerebral tissue
The cerebral tissue pathomorphology HE demonstration of dyeing: visible sham operated rats cerebral tissue structure is tight under the light microscopic, and nucleus is clear, and a matter does not have edema; The obvious heavy structure of model group ischemia side brain tissue impairment is loose, is the space shape, and cyton is dwindled, and becomes triangle Nissl corpusculum and disappears; A plurality of neurons only stay its profile, and endochylema is even eosinophilic staining, karyon pyknosis engrain, and structure disappears.(the obvious swelling necrosis of cell).Use after the compound treatment, find that acute cerebral ischemia damage pathological change obviously alleviates, it is tight relatively than model group to show as the cerebral tissue structure, and the space diminishes around the neurocyte, and the swelling necrosis alleviates to some extent.
3, to the influence of the SOD of MCAO rat cerebral tissue and GSH activity and MDA content
With sham operated rats relatively, the active and GSH content of model group SOD obviously reduces, MDA content significantly raise (P＜0.05 and P＜0.01).Compare with model group, compound recipe group and gingko leaf extract injection group SOD activity and GSH content significantly raise, and MDA content significantly reduces, and difference has significance (P＜0.01), and the prompting investigational agent has the damage of free radical resisting, the effect of protection cerebral tissue.
4, to the influence of MCAO rat infarct volume
Be uniform redness in the section of sham operated rats TTC stained brain, do not see the infarction kitchen range.Visible bigger pale asphyxia infarcted region on the model group brain section.With model control group relatively, compound recipe group and gingko leaf extract injection group Infarction volume significantly reduce (P＜0.05), and compound recipe group and gingko leaf extract injection group more also have significant difference (P＜0.05).
The influence of 5, the MCAO rat being blocked cerebral tissue bcl-2 and caspase-3 expression
Adopt improvement line bolt legal system to make cerebral ischemic reperfusion in rats model and immunohistochemical method, the result shows: compound recipe group bcl-2 positive cell is expressed than model group and is reduced, but still has expression, a little more than sham operated rats, IOD and model group comparing difference are remarkable, P＜0.05; Compare with model group: gingko leaf extract injection group, compound recipe group caspase-3 positive cell all reduce, and positive expression accumulative total optical density IOD has significant difference (P＜0.05).
One, investigational agent of the present invention is to the influence of MCAO rat nervous symptoms
Experiment material
1, medicine and reagent
Be subjected to reagent: the investigational agent outward appearance is lark, content: 20mg/ml, have removing pathogenic heat from blood and toxic substance from the body, and the function of disperse blood stasis and dredge collateral cures mainly the acute ischemic apoplexy.
Positive control drug: gingko leaf extract injection is white in color, content: 7.5mg/ml, have the function of blood circulation promoting and blood stasis dispelling, and cure mainly the acute ischemic apoplexy.
Reagent and medicine:
Compound recipe crude drug water extract-alcohol precipitation extracts active component.
The gingko leaf extract injection Taiwan limited company of biochemical pharmaceutical factory of helping produces lot number: CC213.
2, animal
60 of adult healthy ♂ Wistar rats, the SPF level, body weight 270～290 grams are provided by Beijing Vital River Experimental Animals Technology Co., Ltd., and credit number is SCXK (capital): 2006-0009
Method and result
1, grouping and administration
60 rats are divided into 4 groups according at random principle, are respectively sham operated rats (Sham), model group (Model), gingko leaf extract injection group (positive controls EGB), compound recipe group (F), 15 every group.Administration immediately after the perfusion again, synchronous tail vein injection 0.09% normal saline of model group and sham operated rats 500 μ l, gingko leaf extract injection group tail vein injection (10mg/kg) 500 μ l, compound recipe group gastric infusion (200mg/kg).
2, modeling method
Rat conforms, and intraluminal middle cerebral artery occlusion in rats obturation (MCAO) and re-perfusion model are made in the feed of freely drinking water after 7 days.Weigh, the anesthesia of lumbar injection 10% chloral hydrate solution (0.3ml/100g) is lain on the back and is fixed on the operating-table, and the about 20mm of cervical region median incision length exposes right carotid (CCA), separates external carotid artery (ECA), internal carotid artery (ICA).Ligation CCA and ECA, the ICA hanging wire is standby.Below CCA binding upper end is ECA and ICA crotch, tiltedly cut an osculum, nylon embolus thread ball end is inserted gently, slowly send into ICA, when inserting about 18 ± 0.5mm,, show that the nylon wire pommel is to brain basilar artery ring if there is resistance promptly to stop plug wire.The plug wire process gently lifts the ICA hanging wire, prevents that blood from flowing out from the ICA intracranial segment.After plug wire finishes, with ICA and the ligation together of nylon embolus line, sew up the incision, make nylon wire have 10mm to stay outside the skin with the ICA hanging wire.When the line bolt inserts, pick up counting, behind the ischemia 2h line bolt is extracted gently, form perfusion again.
3, the nervous symptoms of MCAO rat evaluation
According to 5 grades of point systems of foundation such as Zea longa, carry out function of nervous system's scoring respectively, following 0 minute of standard: normal activity in the clear-headed back of rat with after pouring into 24h again; 1 minute: can not fully stretch left fore; 2 minutes: turn-take to the left; 3 minutes: topple over to the left; 4 minutes: can not spontaneously walk disturbance of consciousness.Function of nervous system scoring was at 2～3 minutes and levy male rat with left side Horner ' s and be used for experiment.
EBST experiment: in the clear-headed back of rat with after pouring into 24h again, mention the Mus tail and make the liftoff about 5cm height of rat, observe the rat head left, the direction of right avertence commentaries on classics, departing from midline of body with rat head is as the criterion for about 10 °, then rat is put back to ground, allow its movable 30s, begin again to observe next time.Every rat is repeated this step 20 time.Normally, the equiprobability of not damaged rat deflection to the left and right, promptly respectively be 50%, right side tail putamen hemorrhage rat model obviously greater than to the number of times with sideway swivel, can be thought model success to number of revolutions＞75% of ischemia offside to the number of revolutions of ischemia offside.
Scoring of model control group function of nervous system and offside number of revolutions percentage ratio obviously raise, and compare with sham operated rats, and statistical significance (P＜0.01) is arranged, and rat has tangible nerve injury behind the prompting cerebral ischemia re-pouring.After using compound treatment, scoring of EGB positive controls function of nervous system and offside number of revolutions percentage ratio all have reduction trend, compare with model control group, function of nervous system's scoring and offside number of revolutions level reduce, difference has statistical significance (P＜0.05 and P＜0.01), and prompting compound treatment group has the effect that improves cerebral ischemia-reperfusion injury in rats function of nervous system to see (table 1).
Table 1 be subjected to reagent to the influence of cerebral ischemia-reperfusion injury in rats function of nervous system (
N=10)
(t check: compare with sham operated rats: * P＜0.01; Compare with model group: #P＜0.05, ##P＜0.01)
Two, the present invention is influenced MCAO rat cerebral tissue is morphologic by reagent
Experiment material
1, medicine and reagent
Be subjected to reagent, positive control drug with test 1
2, animal
Adult healthy ♂ Wistar rat, the SPF level, body weight 270～290 grams are provided by Beijing Vital River Experimental Animals Technology Co., Ltd., and credit number is SCXK (capital): 2006-0009
3, instrument
Electronic inverted fluorescence microscope (TE16721 OLYMPUS)
Method and result
1 rat is got for every group at random in the scoring back, 10% chloral hydrate anesthesia (0.3ml/100g, lumbar injection), open the thoracic cavity fast and fully expose heart, puncture rapidly with catheter needle and to cut right atrium one osculum after the left ventricle, with 37 ℃ of 0.9% normal saline 500mL perfusion, flow out limpid liquid to the right auricle, use 4% paraformaldehyde phosphate buffer instead and continue perfusion 200mL, stiff to the animal whole body, till liver turns white, broken end is got brain then, cuts anterior akrencephalon and rear portion cerebellum with blade, puts into 4% paraformaldehyde and continues fixedly 48h, paraffin embedding, doing thickness is the crown sections of 4 μ m brains, conventional H E dyeing, and visible sham operated rats cerebral tissue structure is tight under the light microscopic, nucleus is clear, and a matter does not have edema; The obvious heavy structure of model group ischemia side brain tissue impairment is loose, is the space shape, and cyton is dwindled, and becomes triangle Nissl corpusculum and disappears; A plurality of neurons only stay its profile, and endochylema is even eosinophilic staining, karyon pyknosis engrain, and structure disappears.(the obvious swelling necrosis of cell).The om observation tectology changes.Use after the compound treatment, find that acute cerebral ischemia damage pathological change obviously alleviates, it is tight relatively than model group to show as the cerebral tissue structure, and the space diminishes around the neurocyte, and the swelling necrosis alleviates to some extent.(see figure 1)
Three, the present invention is subjected to the influence of reagent to the SOD of MCAO rat cerebral tissue and GSH activity and MDA content
Experiment material
1, medicine and reagent
Be subjected to reagent, positive control drug with test 1
Reagent: Coomassie brilliant blue protein determination kit, superoxide dismutase (SOD) testing cassete, malonaldehyde (MDA) are measured test kit, micro-reduced glutathion (GSH) and are measured test kit, nitricoxide synthase (NOS) and measure test kit and purchase and build up bio-engineering research institute in Nanjing.
2, animal
Adult healthy ♂ Wistar rat, the SPF level, body weight 270～290 grams are provided by Beijing Vital River Experimental Animals Technology Co., Ltd., and credit number is SCXK (capital): 2006-0009
3, instrument
Distributing refiner (IKA R10 basic made by IKA) fluorescent absorption light microplate reader (Benchmark-p1us 10681 series, Bio Rad Laboratories), low speed refrigerated centrifuge (L535R-1 type, Hunan, Changsha instrument centrifuge instrument company limited), ELISA Plate (Costar 9018 series, Corning Incorporated)
Method and result
Each organizes rat after pouring into 24h again, get cerebral tissue, accurately take by weighing the weight of tissue to be measured, 9 times of 0.9% ice of volume ratio adding sodium chloride solution is made 10% brain tissue homogenate by weight, and is centrifugal, 3000r/min, 10min, get supernatant, press the operation of test kit description, measure SOD, NOS activity and GSH and MDA content respectively.With the bovine serum albumin is standard substance, measures protein content in each sample with the Coomassie brilliant blue method.
Compare with sham operated rats, model group T-NOS, iNOS, cNOS activity all obviously reduce, (P＜0.01 or P＜0.01).Compare with model group, diffusing group of compound recipe the lung-pulse and gingko leaf extract injection group TNOS, the active significantly reduction of iNOS, cNOS, difference has significance (P＜0.01) and Folium Ginkgo extract injection to compare, and compound recipe group T-NOS, iNOS, cNOS activity difference not statistically significant (P＞0.05) see Table 2.
Table 2 mongolian medicine the lung-pulse loose to Ischemia and Reperfusion in vivo in Rats cerebral tissue TNOS, the active influence of iNOS, cNOS (
U/mgprot)
(t check: compare with sham operated rats: * P＜0.01; Compare with model group: #P＜0.01)
Four, the present invention is subjected to the influence of reagent to MCAO rat cerebral infarction volume
Experiment material
1, medicine and reagent
Be subjected to reagent, positive control drug with test 1
TTC stain Beijing money is contained rising sun bio tech ltd (sigma)
2, animal
Adult healthy ♂ Wistar rat, the SPF level, body weight 270～290 grams are provided by Beijing Vital River Experimental Animals Technology Co., Ltd., and credit number is SCXK (capital): 2006-0009
3, instrument
Electronic inverted fluorescence microscope (TE16721 OLYMPUS)
Method and result
Every treated animal is got 5, behind 10% chloral hydrate (0.3ml/100g) the lumbar injection deep anaesthesia, the complete brain of getting breaks end, cut the brain mould with rat and be cut into the thick crown section of 2mm from front to back continuously, totally 6,37 ℃ of lucifuge dyeing of triphenyltetrazolium chloride (TTC) 10min, normal cerebral tissue dye and are that redness, infarction tissue are white.With digital camera every cerebral tissue is taken pictures (jpg form).White cerebral tissue part as the analysis software measured area, is represented cerebral infarction volume with the percentage ratio (%) that accounts for this aspect homonymy hemisphere area through brain infarction area on the opticochiasmatic coronal section through Image-pro plus6.0 domain.
Be uniform redness in the section of sham operated rats TTC stained brain, do not see the infarction kitchen range.Visible bigger pale asphyxia infarcted region on the model group brain section.With model control group relatively, compound recipe group and gingko leaf extract injection group Infarction volume significantly reduce (P＜0.05), and compound recipe group and gingko leaf extract injection group more also have significant difference (P＜0.05) (table 3).
Table 3 compound recipe is to the influence of MCAO/R rat function of nervous system and cerebral infarction volume
(t check; Compare * P＜0.05 with model group; Compare #P＜0.05 with the gingko leaf extract injection group.)
Five, the present invention is subjected to the influence of reagent to MCAO rat infraction cerebral tissue bcl-2 and caspase-3 expression
Experiment material
1, medicine and reagent
Be subjected to reagent, positive control drug with test 1
Immunohistochemistry reagent: anti-Mus Caspase-3 of rabbit and Bcl-2 antibody (BA2142), instant SABC SABC test kit (SA1022), DAB colour reagent box (AR1022) haematoxylin (AR1104) are all purchased in Wuhan doctor's moral biotech firm.
2, animal
Adult healthy ♂ Wistar rat, the SPF level, body weight 270～290 grams are provided by Beijing Vital River Experimental Animals Technology Co., Ltd., and credit number is SCXK (capital): 2006-0009
3, instrument
Electronic inverted fluorescence microscope (TE16721 OLYMPUS)
Method and result
3 rats are got for every group at random in the scoring back, behind 10% chloral hydrate (0.3ml/100g) the lumbar injection deep anaesthesia, open the thoracic cavity fast and fully expose heart, puncture rapidly with catheter needle and to cut right atrium one osculum after the left ventricle, with 37 ℃ of 0.9% normal saline 500mL perfusion, flow out limpid liquid to the right auricle, use 4% paraformaldehyde phosphate buffer instead and continue perfusion 200mL, stiff to the animal whole body, till liver turns white, broken end is got brain then, cut anterior akrencephalon and rear portion cerebellum with blade, put into 4% paraformaldehyde and continue fixedly 48h, paraffin embedding, doing thickness is the crown sections of 4 μ m brains, routine dewaxes to water, presses the operation of test kit description step, the anti-Mus bcl-2 of rabbit antibody concentration (1: 150), caspase-3 antibody concentration (1: 100), kytoplasm or the karyon positive cell of person that has the brown particle is observed in DAB colour developing, light microscopic down.The negative control section does not add one and resists, and uses 0.1molL
-1PBS replaces, and positive reaction do not occur.Every rat is got 3 serial section, every section 5 visuals field of picked at random under 400 times of light microscopics, keeping microscope same light intensity, digital camera to turn off function such as AWB, all take pictures with manually being provided with etc. under the condition, with Image pro plus6.0 image processing system analyze each visual field positive expression accumulative total optical density value (IOD).
The SABC mirror finds that down each group all has neurocyte nuclear chromatin in various degree to rupture, assemble; And then pyknosis, nuclear membrane disintegrate, cytoplasm cohesion, pyknosis and vacuolation.Bcl-2 protein expression, its positive cell are that cell membrane and cytoplasm are pale brown color dyeing, and its expression scope is based on cortex, and Hippocampus is expressed less.The sham operated rats cerebral tissue has only a small amount of Bcl-2 positive cell; Model group Bcl-2 positive staining neurocyte mainly is positioned at the ischemia peripheral region, and brown yellow granule is arranged in the endochylema, and it is darker to develop the color, the nucleus understain; The visible bcl-2 positive cell of gingko leaf extract injection group, but express few than model group relatively; Compound recipe group bcl-2 positive cell is expressed than model group and is reduced, but still has expression, and a little more than sham operated rats, IOD and model group comparing difference are remarkable, P＜0.05 (Fig. 3 and table 4).
The sham operated rats cerebral tissue almost can not find the Caspase-3 positive cell.Model group Caspase-3 positive staining neuron mainly is positioned at the ischemia peripheral region, and the ischemia center is less, and brown yellow granule is arranged in the endochylema, the nucleus understain.Compare with model group: gingko leaf extract injection group, compound recipe group caspase-3 positive cell all reduce, and positive expression accumulative total optical density IOD has significant difference (P＜0.05).(Fig. 2 and table 4)
Table 4 be subjected to reagent to the influence of casepase3 of MCAO/R rat cerebral tissue and Bcl-2 protein expression (IOD,
)
(t check; Compare #P＜0.05 with sham operated rats; Compare * P＜0.05 with model group; Compare △ P＜0.05 with the gingko leaf extract injection group.)
Claims (6)
1. a compound recipe for the treatment of apoplexy is characterized in that being made up of following bulk drugs: Fructus Chebulae, Rhizoma Picrorhizae, Flos Caryophylli, Semen Myristicae, the Radix Aucklandiae, Rhizoma Bistortae, Radix Glehniae, Artemisia frigida Willd., Lignum Santali Albi, Concretio Silicea Bambusae, Resina Liquidambaris, HEIYUNXIANG, dried Cor Leporis, Lignum Aquilariae Resinatum, Flos Inulae, Flos Bombacis Malabarici, artificial Calculus Bovis, Semen Strychni (processed), Radix Aconiti Kusnezoffii Preparata.
2. compound recipe as claimed in claim 1; it is characterized in that described crude drug weight proportion is: Fructus Chebulae 30g～60g; Rhizoma Picrorhizae 20g～50g; Flos Caryophylli, Semen Myristicae, the Radix Aucklandiae, Rhizoma Bistortae, Radix Glehniae are 10g～30g, and Artemisia frigida Willd., Lignum Santali Albi, Concretio Silicea Bambusae, Resina Liquidambaris, HEIYUNXIANG, dried Cor Leporis, Lignum Aquilariae Resinatum, Flos Inulae, Flos Bombacis Malabarici, artificial Calculus Bovis, Semen Strychni (processed), Radix Aconiti Kusnezoffii Preparata are 2g～20g.
3. compound recipe as claimed in claim 1; it is characterized in that described crude drug optimum ratio is: Fructus Chebulae 25g, Rhizoma Picrorhizae 20g, Flos Caryophylli, Semen Myristicae, the Radix Aucklandiae, Rhizoma Bistortae, each 10g of Radix Glehniae, Artemisia frigida Willd., Lignum Santali Albi, Concretio Silicea Bambusae, Resina Liquidambaris, HEIYUNXIANG, each 5g of dried Cor Leporis, Lignum Aquilariae Resinatum, Flos Inulae, Flos Bombacis Malabarici, artificial Calculus Bovis, Semen Strychni (processed), each 2.5g of Radix Aconiti Kusnezoffii Preparata
4. method for preparing as the described compound active composition of arbitrary claim in the claim 1 to 3 is characterized in that following preparation method:
(1) preparation of active component extractum
After getting the crude drug mix homogeneously and pulverizing slightly, decoct with water and extract 3 times, each 1.5～2 hours, add water 2～4 parts by volume, merges three times extracting solution, centrifugal going precipitated.Supernatant adds 3 times of amounts of dehydrated alcohol, fully stirs, and decompress filter, the filtrate partial rotation is evaporated to nothing alcohol flavor and obtains sample.Be ground into coarse powder, merge,, filter, merge water boiling and extraction liquid with water boiling and extraction, concentrating under reduced pressure, drying is pulverized, and gets active component extractum.
(2) preparation of pill, tablet, capsule
Get above-mentioned extractum, vacuum drying is ground into fine powder, adds proper pharmaceutical excipients, crosses the 12-20 mesh sieve and gets the semi-finished product powder; The semi-finished product direct powder compression is promptly got tablet; The semi-finished product powder packed into promptly get capsule in the hungry area shell; The semi-finished product powder is granulated, and repressed method is made the ball coating and is promptly got pill;
(3) preparation of granule
Get above-mentioned extractum, add proper pharmaceutical excipients, make soft material, pushed the 12-20 mesh sieve with granulator and become granule, be drying to obtain:
5. one kind is the preparation of main active with the described compound recipe of arbitrary claim in the claim 1 to 3, it is characterized in that being mainly oral formulations.
6. has application in the treatment apoplexy medicine as compound recipe as described in arbitrary claim in the claim 1 to 3 in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105332931A CN101972429B (en) | 2010-11-05 | 2010-11-05 | Compound preparation for treating stroke and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105332931A CN101972429B (en) | 2010-11-05 | 2010-11-05 | Compound preparation for treating stroke and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101972429A true CN101972429A (en) | 2011-02-16 |
| CN101972429B CN101972429B (en) | 2012-07-04 |
Family
ID=43572362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105332931A Expired - Fee Related CN101972429B (en) | 2010-11-05 | 2010-11-05 | Compound preparation for treating stroke and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101972429B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055064A (en) * | 2011-10-23 | 2013-04-24 | 天津大学 | Pharmaceutical composition for treating cerebral apoplexy and preparation method |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022140536A1 (en) * | 2020-12-24 | 2022-06-30 | Natreon, Inc. | Neuroprotective phyllanthus emblica-containing compositions and methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623596A (en) * | 2003-12-03 | 2005-06-08 | 乌力吉·特古斯 | Mongolian medicine compound preparation for curing cardiac disease |
| CN101116684A (en) * | 2006-08-02 | 2008-02-06 | 奥·乌力吉 | Mongolian medicine for treating cerebrovascular disease |
| CN101703753A (en) * | 2009-11-05 | 2010-05-12 | 甘肃奇正藏药有限公司 | Medicinal composition powders or granules for treating whitevein and preparation method thereof |
-
2010
- 2010-11-05 CN CN2010105332931A patent/CN101972429B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623596A (en) * | 2003-12-03 | 2005-06-08 | 乌力吉·特古斯 | Mongolian medicine compound preparation for curing cardiac disease |
| CN101116684A (en) * | 2006-08-02 | 2008-02-06 | 奥·乌力吉 | Mongolian medicine for treating cerebrovascular disease |
| CN101703753A (en) * | 2009-11-05 | 2010-05-12 | 甘肃奇正藏药有限公司 | Medicinal composition powders or granules for treating whitevein and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《中国少数民族传统医药大系》 20000331 奇玲 等 补心宝 内蒙古科学技术出版社 第338页 1-6 , 1 * |
| 《国际药学研究杂志》 20100831 刘庆山 等 应用快速色谱技术构建少数民族大复方组分库的方法学研究 第310-314页 1-6 第37卷, 第4期 2 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055064A (en) * | 2011-10-23 | 2013-04-24 | 天津大学 | Pharmaceutical composition for treating cerebral apoplexy and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101972429B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107929420B (en) | Traditional Chinese medicine composition for improving qi and blood functions and immunity of human body and detection method | |
| CN102048959A (en) | Dendrobium candidum compound preparation capable of regulating function of human body in two-way manner and preparation method thereof | |
| CN111743934A (en) | Traditional Chinese medicine composition for regulating intestinal flora and application thereof | |
| CN103355655A (en) | Composition with alimentary anemia improving function and preparation method of composition | |
| CN104208418A (en) | Rosa laevigata michx health oral solution for securing essence, reducing urination and tonifying kidneys and preparation method thereof | |
| CN103446525A (en) | Traditional Chinese medicine composition for treating skin diseases as well as preparation method and application of traditional Chinese medicine composition | |
| CN101972429B (en) | Compound preparation for treating stroke and preparation method thereof | |
| CN101062130B (en) | Yang recuperating decoction soft capsule preparing method | |
| CN103041137A (en) | Pharmaceutical composition for preventing and treating senile dementia, and preparation method thereof | |
| CN110025664B (en) | Pharmaceutical composition for preventing and treating cerebral infarction and/or vascular dementia and application thereof | |
| US10799549B2 (en) | Hepatoprotective traditional chinese medicine composition containing fructus ligustri lucidi, herba exliptae, radix paeoniae alba, rhizoma curcumae longae and clam extract, preparation method and use thereof | |
| CN115414407B (en) | Zhuang medicine compound medicine for treating ischemic cerebral apoplexy and preparation method thereof | |
| CN102846871B (en) | Chinese herbal preparation for treating liver-fire ascending type supraorbital neuralgia and preparation method thereof | |
| CN102600321A (en) | Chinese medicinal compound preparation for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN102106993B (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN109718304A (en) | Improve the Chinese medicine composition of the microcirculation of human body cardio and vascular function and pre- preventing thrombosis | |
| CN104173521B (en) | A kind of pharmaceutical composition and its preparation method giving birth to able-bodied sun | |
| CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof | |
| CN108653658B (en) | Traditional Chinese medicine composition for improving vascular cognitive dysfunction and application thereof | |
| CN115813972B (en) | Zhuang medicine compound medicine for treating acute stage of ischemic stroke and preparation method thereof | |
| CN108126134B (en) | Traditional Chinese medicine compound composition for treating liver injury, preparation method and application thereof | |
| CN108815342B (en) | Traditional Chinese medicine composition for treating male infertility | |
| CN101244127B (en) | Medicament for treating vascular dementia | |
| CN100560087C (en) | Pharmaceutical composition of treatment malignant tumor and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CENTRAL UNIVERSITY FOR NATIONALITIES Free format text: FORMER OWNER: LIU QINGSHAN Effective date: 20121116 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20121116 Address after: 100081 Beijing, Zhongguancun, South Street, No. 27, No. Patentee after: Central University for Nationalities Address before: 100081 Haidian District Medical College, Minzu University of China, Beijing Patentee before: Liu Qingshan |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20121105 |